Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemical adherence testing-guided intervention versus standard of care in patients with hypertension who are non-adherent to antihypertensive treatment in the UK (OUTREACH): a multicentre, randomised controlled trial.

The Lancet. Primary care·2026
Same author

Clinical impact of Takotsubo syndrome in patients with stroke.

Heart (British Cardiac Society)·2026
Same author

Grüntzig's technique, relearnt.

The British journal of cardiology·2026
Same author

Additive value of repeat transthoracic echocardiography for excluding infective endocarditis in patients with Staphylococcus aureus bacteremia.

Journal of cardiovascular imaging·2026
Same author

The tau of angina with non-obstructive coronary arteries.

European heart journal·2025
Same author

Drug-coated balloon angioplasty and stenting for coronary artery lesions.

Lancet (London, England)·2025

Related Experiment Video

Updated: Jun 21, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.

Nikolaos Tzemos1, Pitt O Lim, Thomas M MacDonald

  • 1Hypertension Research Centre, Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. nikotzemos@yahoo.co.uk

Cardiovascular Therapeutics
|July 17, 2009
PubMed
Summary
This summary is machine-generated.

Valsartan improved endothelial dysfunction in hypertension by enhancing nitric oxide (NO) release and function, unlike amlodipine. This study shows valsartan

Related Experiment Videos

Last Updated: Jun 21, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Endothelial dysfunction is a key predictor of cardiac outcomes in hypertension.
  • Reversing endothelial dysfunction is a critical therapeutic goal.

Purpose of the Study:

  • To compare the effects of valsartan (angiotensin type 1 receptor blocker) and amlodipine (calcium channel blocker) on forearm resistance artery endothelial function in hypertensive subjects.
  • To investigate the impact of these drugs on nitric oxide (NO)-dependent and NO-independent pathways.

Main Methods:

  • A double-blind, crossover trial involving 25 hypertensive patients randomized to 16-week treatments with valsartan or amlodipine.
  • Intra-arterial infusions of acetylcholine (ACh) and N(G)-monomethyl-L-arginine (L-NMMA) assessed endothelium-dependent NO release and NO-independent pathways.

Main Results:

  • Both valsartan and amlodipine reduced blood pressure similarly.
  • Valsartan significantly improved acetylcholine-induced vasodilation, indicating enhanced NO release, while amlodipine did not.
  • Both drugs increased the vasoconstrictive response to L-NMMA, suggesting effects on NO bioavailability.
  • Valsartan uniquely enhanced vasodilation in the presence of L-NMMA, indicating improvement in NO-independent pathways.

Conclusions:

  • Valsartan effectively reversed peripheral endothelial dysfunction in hypertensive patients through both NO-dependent and NO-independent mechanisms.
  • For equivalent blood pressure reduction, valsartan demonstrated superior effects on endothelial function compared to amlodipine.